TRAIL在乳腺癌组织中的表达  

Expressions of TRAIL in breast cancer

作　　者：杨雷[1] 孔焕育[2] 曹莹[2] 

机构地区：[1]解放军第458医院肿瘤科,广东广州510602 [2]南方医科大学新药评价中心,广东广州510515

出　　处：《现代肿瘤医学》2013年第4期776-778,共3页Journal of Modern Oncology

摘　　要：目的:研究肿瘤坏死因子相关凋亡诱导配体(TRAIL)在乳腺癌组织中的表达。方法:免疫组化法检测TRAIL在乳腺癌组织中的表达。结果:TRAIL在乳腺不典型增生和腺癌中的表达无统计学差异。TRAIL的阳性表达水平与乳腺癌组织的分化程度呈正相关,即分化程度愈高,TRAIL表达水平愈高。TRAIL在不同临床分期乳腺癌组织中的表达无统计学差异,与有无淋巴结转移无统计学差异。结论:本实验从凋亡调节因子方面支持了不典型增生为癌前病变的观点,TRAIL蛋白的表达可能与乳腺癌组织的恶性程度有关,与肿瘤的生物学行为无关。Objective： To investigate the expressions of tumor necrosis factor related apoptosis inducing ligand （TRAIL） in human breast cancer tissues, Methods：We measured the expression of TRAIL in breast cancer tissues by immunochemical technique. Results： Expression of TRAIL in breast cancer tissues was higher in high and middle differential adenocarcinoma than low and not differential adenocarcinoma（P 〈 0.01 ）. But it had no relation between early, middle clinic stage group and late group（ P 〉 0.05 ）, and metastasis of lymph node （ P 〉 0. 05 ）. Conclusion： The expression of TRAIL acceptor correlates with the occurrence and development of breast cancer closely, correlates with the clinic stages of breast cancer negatively, but not related with the metastasis.

关 键 词：乳腺癌 肿瘤坏死因子相关凋亡诱导配体 免疫组化 

分 类 号：R737.9[医药卫生—肿瘤]